Award Winner 2022

In this publication, the team around Dr. Velin shows that Helicobacter pylori serology might help to personalize cancer immunotherapies. Immune checkpoint inhibitors (ICIs) aim to stimulate the antitumor immune responses in cancer Patients. However, despite unprecedented results of these cancer immunotherapies, some patients do not respond to ICIs. This study shows that Helicobacter pylori infected hosts are among the ICIs lowest responders.

^{Oster P. et al., Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies. Gut. 2022 Mar;71(3):457-466.}